Login Register Cart 0
Generic placeholder image

Current Neuropharmacology

Editor-in-Chief

ISSN (Print): 1570-159X
ISSN (Online): 1875-6190

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Systematic Review Article

Herb-drug Interactions in Neuropsychiatric Pharmacotherapy – A Review of Clinically Relevant Findings

Author(s): Tram T. Le, Sarah R. McGrath and Pius S. Fasinu*

Volume 20, Issue 9, 2022

Published on: 30 March, 2022

Page: [1736 - 1751] Pages: 16

DOI: 10.2174/1570159X19666210809100357

Price: $65

Abstract

The management of neuropsychiatric disorders relies heavily on pharmacotherapy. The use of herbal products as complimentary medicine, often concomitantly, is common among patients taking prescription neuropsychiatric drugs. Herb-drug interaction, a clinical consequence of this practice, may jeopardize the success of pharmacotherapy in neuropsychiatry. Besides the wellknown ability of phytochemicals to inhibit and/or induce drug-metabolizing enzymes and transport proteins, several phytoconstituents are capable of exerting pharmacological effects on the central nervous system. This study reviewed the relevant literature and identified 13 commonly used herbal products - celery, echinacea, ginkgo, ginseng, hydroxycut, kava, kratom, moringa, piperine, rhodiola, St. John’s wort, terminalia/commiphora ayurvedic mixture and valerian - which have shown clinically relevant interactions with prescription drugs used in the management of neuropsychiatric disorders. The consequent pharmacokinetic and pharmacodynamic interactions with orthodox medications often result in deleterious clinical consequences. This underscores the importance of caution in herb-drug co-medication.

Keywords: Complimentary medicine, herb-drug interaction, neuropsychiatry, pharmacotherapy, St. John’s wort, antipsychotic drug.

« Previous Next »
Graphical Abstract

[1]
Khan, M.S.; Ahmad, I. Herbal medicine: Current trends and future prospects. New Look to phytomedicine; Academic Press, 2019, pp. 3-13.
[2]
Smith, T.; May, G.; Eckl, V.; Reynolds, C.M. US sales of herbal supplements increase by 8.6% in 2019. HerbalGram, 2020, 127, 54-69.
[3]
Global News Wire. Market Research Future: Herbal Medicine Market Report. Available from: https://www. globenewswire.com/news-release/2019/04/03/1796359/0/en/Herbal-Medicine-Market-Value-to-Surpass-USD-129-Billion-Revenue-Mark-by-2023-at-5-88-CAGR-Predicts-Market-Research-Future.html (Accessed April 23, 2021).
[4]
Snyder, F.J.; Dundas, M.L.; Kirkpatrick, C.; Neill, K.S. Use and safety perceptions regarding herbal supplements: a study of older persons in southeast Idaho. J. Nutr. Elder., 2009, 28(1), 81-95.
[http://dx.doi.org/10.1080/01639360802634043] [PMID: 19234997]
[5]
Shaw, D.; Graeme, L.; Pierre, D.; Elizabeth, W.; Kelvin, C. Pharmacovigilance of herbal medicine. J. Ethnopharmacol., 2012, 140(3), 513-518.
[http://dx.doi.org/10.1016/j.jep.2012.01.051] [PMID: 22342381]
[6]
Rashrash, M.; Schommer, J.C.; Brown, L.M. Prevalence and predictors of herbal medicine use among adults in the United States. J. Patient Exp., 2017, 4(3), 108-113.
[http://dx.doi.org/10.1177/2374373517706612] [PMID: 28959715]
[7]
Zhang, Z.J.; Tan, Q.R.; Tong, Y.; Wang, X.Y.; Wang, H.H.; Ho, L.M.; Wong, H.K.; Feng, Y.B.; Wang, D.; Ng, R.; McAlonan, G.M.; Wang, C.Y.; Wong, V.T. An epidemiological study of concomitant use of Chinese medicine and antipsychotics in schizophrenic patients: implication for herb-drug interaction. PLoS One, 2011, 6(2), e17239.
[http://dx.doi.org/10.1371/journal.pone.0017239] [PMID: 21359185]
[8]
Agbabiaka, T.B.; Spencer, N.H.; Khanom, S.; Goodman, C. Prevalence of drug-herb and drug-supplement interactions in older adults: a cross-sectional survey. Br. J. Gen. Pract., 2018, 68(675), e711-e717.
[http://dx.doi.org/10.3399/bjgp18X699101] [PMID: 30249608]
[9]
Delgoda, R.; Younger, N.; Barrett, C.; Braithwaite, J.; Davis, D. The prevalence of herbs use in conjunction with conventional medicines in Jamaica. Complement. Ther. Med., 2010, 18(1), 13-20.
[http://dx.doi.org/10.1016/j.ctim.2010.01.002] [PMID: 20178874]
[10]
McCune, J.S.; Hatfield, A.J.; Blackburn, A.A.; Leith, P.O.; Livingston, R.B.; Ellis, G.K. Potential of chemotherapy-herb interactions in adult cancer patients. Support. Care Cancer, 2004, 12(6), 454-462.
[http://dx.doi.org/10.1007/s00520-004-0598-1] [PMID: 14991387]
[11]
Bailey, D.G.; Spence, J.D.; Munoz, C.; Arnold, J.M. Interaction of citrus juices with felodipine and nifedipine. Lancet, 1991, 337(8736), 268-269.
[http://dx.doi.org/10.1016/0140-6736(91)90872-M] [PMID: 1671113]
[12]
Hall, S.D.; Wang, Z.; Huang, S.M.; Hamman, M.A.; Vasavada, N.; Adigun, A.Q.; Hilligoss, J.K.; Miller, M.; Gorski, J.C. The interaction between St John’s wort and an oral contraceptive. Clin. Pharmacol. Ther., 2003, 74(6), 525-535.
[http://dx.doi.org/10.1016/j.clpt.2003.08.009] [PMID: 14663455]
[13]
Zhang, J.; Tian, L.; Xie, B. Bleeding due to a probable interaction between warfarin and Gouqizi (Lycium Barbarum L.). Toxicol. Rep., 2015, 2, 1209-1212.
[http://dx.doi.org/10.1016/j.toxrep.2015.08.011] [PMID: 28962463]
[14]
Akhondzadeh, S.; Maleki, J. Herbal medicines in the treatment of psychiatric neurological disorders. Iran. J. Psychiatry, 2006, 1, 1-11.
[15]
Wong, A.H.; Smith, M.; Boon, H.S. Herbal remedies in psychiatric practice. Arch. Gen. Psychiatry, 1998, 55(11), 1033-1044.
[http://dx.doi.org/10.1001/archpsyc.55.11.1033] [PMID: 9819073]
[16]
Khalid, Z.; Osuagwu, F.C.; Shah, B.; Roy, N.; Dillon, J.E.; Bradley, R. Celery root extract as an inducer of mania induction in a patient on venlafaxine and St John’s Wort. Postgrad. Med., 2016, 128(7), 682-683.
[http://dx.doi.org/10.1080/00325481.2016.1218263] [PMID: 27467225]
[17]
Gorski, J.C.; Huang, S.M.; Pinto, A.; Hamman, M.A.; Hilligoss, J.K.; Zaheer, N.A.; Desai, M.; Miller, M.; Hall, S.D. The effect of echinacea (Echinacea purpurea root) on cytochrome P450 activity in vivo. Clin. Pharmacol. Ther., 2004, 75(1), 89-100.
[http://dx.doi.org/10.1016/j.clpt.2003.09.013] [PMID: 14749695]
[18]
Lei, H.P.; Ji, W.; Lin, J.; Chen, H.; Tan, Z.R.; Hu, D.L.; Liu, L.J.; Zhou, H.H. Effects of Ginkgo biloba extract on the pharmacokinetics of bupropion in healthy volunteers. Br. J. Clin. Pharmacol., 2009, 68(2), 201-206.
[http://dx.doi.org/10.1111/j.1365-2125.2009.03442.x] [PMID: 19694739]
[19]
Lin, Y.Y.; Chu, S.J.; Tsai, S.H. Association between priapism and concurrent use of risperidone and Ginkgo biloba. Mayo Clin. Proc., 2007, 82(10), 1289-1290.
[http://dx.doi.org/10.4065/82.10.1289] [PMID: 17908535]
[20]
Galluzzi, S.; Zanetti, O.; Binetti, G.; Trabucchi, M.; Frisoni, G.B. Coma in a patient with Alzheimer’s disease taking low dose trazodone and gingko biloba. J. Neurol. Neurosurg. Psychiatry, 2000, 68(5), 679-680.
[http://dx.doi.org/10.1136/jnnp.68.5.679a] [PMID: 10836866]
[21]
Kupiec, T.; Raj, V. Fatal seizures due to potential herb-drug interactions with Ginkgo biloba. J. Anal. Toxicol., 2005, 29(7), 755-758.
[http://dx.doi.org/10.1093/jat/29.7.755] [PMID: 16419414]
[22]
Granger, A.S. Ginkgo biloba precipitating epileptic seizures. Age Ageing, 2001, 30(6), 523-525.
[http://dx.doi.org/10.1093/ageing/30.6.523] [PMID: 11742783]
[23]
Yasui-Furukori, N.; Furukori, H.; Kaneda, A.; Kaneko, S.; Tateishi, T. The effects of Ginkgo biloba extracts on the pharmacokinetics and pharmacodynamics of donepezil. J. Clin. Pharmacol., 2004, 44(5), 538-542.
[http://dx.doi.org/10.1177/0091270004264161] [PMID: 15102875]
[24]
Uchida, S.; Yamada, H.; Li, X.D.; Maruyama, S.; Ohmori, Y.; Oki, T.; Watanabe, H.; Umegaki, K.; Ohashi, K.; Yamada, S. Effects of Ginkgo biloba extract on pharmacokinetics and pharmacodynamics of tolbutamide and midazolam in healthy volunteers. J. Clin. Pharmacol., 2006, 46(11), 1290-1298.
[http://dx.doi.org/10.1177/0091270006292628] [PMID: 17050793]
[25]
Robertson, S.M.; Davey, R.T.; Voell, J.; Formentini, E.; Alfaro, R.M.; Penzak, S.R. Effect of Ginkgo biloba extract on lopinavir, midazolam and fexofenadine pharmacokinetics in healthy subjects. Curr. Med. Res. Opin., 2008, 24(2), 591-599.
[http://dx.doi.org/10.1185/030079908X260871] [PMID: 18205997]
[26]
Zuo, X.C.; Zhang, B.K.; Jia, S.J.; Liu, S.K.; Zhou, L.Y.; Li, J.; Zhang, J.; Dai, L.L.; Chen, B.M.; Yang, G.P.; Yuan, H. Effects of Ginkgo biloba extracts on diazepam metabolism: a pharmacokinetic study in healthy Chinese male subjects. Eur. J. Clin. Pharmacol., 2010, 66(5), 503-509.
[http://dx.doi.org/10.1007/s00228-010-0795-4] [PMID: 20186406]
[27]
Malati, C.Y.; Robertson, S.M.; Hunt, J.D.; Chairez, C.; Alfaro, R.M.; Kovacs, J.A.; Penzak, S.R. Influence of Panax ginseng on cytochrome P450 (CYP)3A and P-glycoprotein (P-gp) activity in healthy participants. J. Clin. Pharmacol., 2012, 52(6), 932-939.
[http://dx.doi.org/10.1177/0091270011407194] [PMID: 21646440]
[28]
Jones, B.D.; Runikis, A.M. Interaction of ginseng with phenelzine. J. Clin. Psychopharmacol., 1987, 7(3), 201-202.
[http://dx.doi.org/10.1097/00004714-198706000-00030] [PMID: 3597812]
[29]
Cvetanovich, G.L.; Ramakrishnan, P.; Klein, J.P.; Rao, V.R.; Ropper, A.H. Reversible cerebral vasoconstriction syndrome in a patient taking citalopram and Hydroxycut: a case report. J. Med. Case Reports, 2011, 5(548), 548.
[http://dx.doi.org/10.1186/1752-1947-5-548] [PMID: 22074635]
[30]
Almeida, J.C.; Grimsley, E.W. Coma from the health food store: interaction between kava and alprazolam. Ann. Intern. Med., 1996, 125(11), 940-941.
[http://dx.doi.org/10.7326/0003-4819-125-11-199612010-00023] [PMID: 8967683]
[31]
Schelosky, L.; Raffauf, C.; Jendroska, K.; Poewe, W. Kava and dopamine antagonism. J. Neurol. Neurosurg. Psychiatry, 1995, 58(5), 639-640.
[http://dx.doi.org/10.1136/jnnp.58.5.639] [PMID: 7745421]
[32]
Hughes, R.L. Fatal combination of mitragynine and quetiapine - a case report with discussion of a potential herb-drug interaction. Forensic Sci. Med. Pathol., 2019, 15(1), 110-113.
[http://dx.doi.org/10.1007/s12024-018-0049-9] [PMID: 30498933]
[33]
Kang, Y.C.; Chen, M.H.; Lai, S.L. Potentially unsafe herb-drug interactions between a commercial product of Noni juice and phenytoin-a case report. Acta Neurol. Taiwan., 2015, 24(2), 43-46.
[PMID: 26179835]
[34]
Rezaee, M.M.; Kazemi, S.; Kazemi, M.T.; Gharooee, S.; Yazdani, E.; Gharooee, H.; Shiran, M.R.; Moghadamnia, A.A. The effect of piperine on midazolam plasma concentration in healthy volunteers, a research on the CYP3A-involving metabolism. Daru, 2014, 22(1), 8.
[http://dx.doi.org/10.1186/2008-2231-22-8] [PMID: 24398010]
[35]
Pattanaik, S.; Hota, D.; Prabhakar, S.; Kharbanda, P.; Pandhi, P. Effect of piperine on the steady-state pharmacokinetics of phenytoin in patients with epilepsy. Phytother. Res., 2006, 20(8), 683-686.
[http://dx.doi.org/10.1002/ptr.1937] [PMID: 16767797]
[36]
Pattanaik, S.; Hota, D.; Prabhakar, S.; Kharbanda, P.; Pandhi, P. Pharmacokinetic interaction of single dose of piperine with steady-state carbamazepine in epilepsy patients. Phytother. Res., 2009, 23(9), 1281-1286.
[http://dx.doi.org/10.1002/ptr.2676] [PMID: 19283724]
[37]
Maniscalco, I.; Toffol, E.; Giupponi, G.; Conca, A. The interaction of Rhodiola rosea (ironwort) and antidepressants. Neuropsychiatr., 2015, 29, 36-38.
[http://dx.doi.org/10.1007/s40211-014-0124-8] [PMID: 25413939]
[38]
Markowitz, J.S.; Donovan, J.L.; DeVane, C.L.; Taylor, R.M.; Ruan, Y.; Wang, J.S.; Chavin, K.D. Effect of St John’s wort on drug metabolism by induction of cytochrome P450 3A4 enzyme. JAMA, 2003, 290(11), 1500-1504.
[http://dx.doi.org/10.1001/jama.290.11.1500] [PMID: 13129991]
[39]
Johne, A.; Schmider, J.; Brockmöller, J.; Stadelmann, A.M.; Störmer, E.; Bauer, S.; Scholler, G.; Langheinrich, M.; Roots, I. Decreased plasma levels of amitriptyline and its metabolites on comedication with an extract from St. John’s wort (Hypericum perforatum). J. Clin. Psychopharmacol., 2002, 22(1), 46-54.
[http://dx.doi.org/10.1097/00004714-200202000-00008] [PMID: 11799342]
[40]
Milton, J.C.; Abdulla, A. Prolonged oro-facial dystonia in a 58 year old female following therapy with bupropion and St John’s Wort. Br. J. Clin. Pharmacol., 2007, 64(5), 717-718.
[http://dx.doi.org/10.1111/j.1365-2125.2007.02962.x] [PMID: 17578477]
[41]
Van Strater, A.C.; Bogers, J.P. Interaction of St. John’s wort (Hypericum perforatum) with clozapine. Int. Clin. Psychopharmacol., 2012, 27(2), 121-124.
[http://dx.doi.org/10.1097/YIC.0b013e32834e8afd] [PMID: 22113252]
[42]
Dresser, G.K.; Schwarz, U.I.; Wilkinson, G.R.; Kim, R.B. Coordinate induction of both cytochrome P4503A and MDR1 by St John’s wort in healthy subjects. Clin. Pharmacol. Ther., 2003, 73(1), 41-50.
[http://dx.doi.org/10.1067/mcp.2003.10] [PMID: 12545142]
[43]
Gordon, J.B. SSRIs and St.John’s Wort: possible toxicity? Am. Fam. Physician, 1998, 57(5), 950-953, 953.
[PMID: 9518947]
[44]
Lantz, M.S.; Buchalter, E.; Giambanco, V.St. John’s wort and antidepressant drug interactions in the elderly. J. Geriatr. Psychiatry Neurol., 1999, 12(1), 7-10.
[http://dx.doi.org/10.1177/089198879901200103] [PMID: 10447148]
[45]
Prasad, K.P.; Tharangani, P.G.; Samaranayake, C.N. Recurrent relapses of depression in a patient established on sertraline after taking herbal medicinal mixtures--a herb-drug interaction? J. Psychopharmacol., 2009, 23(2), 216-219.
[http://dx.doi.org/10.1177/0269881108089808] [PMID: 18515463]
[46]
Donovan, J.L.; DeVane, C.L.; Chavin, K.D.; Wang, J.S.; Gibson, B.B.; Gefroh, H.A.; Markowitz, J.S. Multiple night-time doses of valerian (Valeriana officinalis) had minimal effects on CYP3A4 activity and no effect on CYP2D6 activity in healthy volunteers. Drug Metab. Dispos., 2004, 32(12), 1333-1336.
[http://dx.doi.org/10.1124/dmd.104.001164] [PMID: 15328251]
[47]
Carrasco, M.C.; Vallejo, J.R.; Pardo-de-Santayana, M.; Peral, D.; Martin, M.A.; Altimiras, J. Interactions of Valeriana officinalis L. and Passiflora incarnata L. in a patient treated with lorazepam. Phytother. Res., 2009, 23(12), 1795-1796.
[PMID: 19441067]
[48]
Nguyen, S.; Huang, H.; Foster, B.C.; Tam, T.W.; Xing, T.; Smith, M.L.; Arnason, J.T.; Akhtar, H. Antimicrobial and P450 inhibitory properties of common functional foods. J. Pharm. Pharm. Sci., 2014, 17(2), 254-265.
[http://dx.doi.org/10.18433/J3P599] [PMID: 24934554]
[49]
Deng, X.; Pu, Q.; Wang, E.; Yu, C. Celery extract inhibits mouse CYP2A5 and human CYP2A6 activities via different mechanisms. Oncol. Lett., 2016, 12(6), 5309-5314.
[http://dx.doi.org/10.3892/ol.2016.5317] [PMID: 28101244]
[50]
Rheeders, M.; Bouwer, M.; Goosen, T.C. Drug-drug interaction after single oral doses of the furanocoumarin methoxsalen and cyclosporine. J. Clin. Pharmacol., 2006, 46(7), 768-775.
[http://dx.doi.org/10.1177/0091270006288732] [PMID: 16809802]
[51]
Siska, S.; Mun Im, A.; Bahtiar, A.; Suyatna, F.D. Effect of apium graveolens extract administration on the pharmacokinetics of captopril in the plasma of rats. Sci. Pharm., 2018, 86(1), 6.
[http://dx.doi.org/10.3390/scipharm86010006] [PMID: 29462958]
[52]
Jakovljevic, V.; Raskovic, A.; Popovic, M.; Sabo, J. The effect of celery and parsley juices on pharmacodynamic activity of drugs involving cytochrome P450 in their metabolism. Eur. J. Drug Metab. Pharmacokinet., 2002, 27(3), 153-156.
[http://dx.doi.org/10.1007/BF03190450] [PMID: 12365194]
[53]
Awortwe, C.; Manda, V.K.; Avonto, C.; Khan, S.I.; Khan, I.A.; Walker, L.A.; Bouic, P.J.; Rosenkranz, B. Echinacea purpurea up-regulates CYP1A2, CYP3A4 and MDR1 gene expression by activation of pregnane X receptor pathway. Xenobiotica, 2015, 45(3), 218-229.
[http://dx.doi.org/10.3109/00498254.2014.973930] [PMID: 25377539]
[54]
Hansen, T.S.; Nilsen, O.G. In vitro CYP3A4 metabolism: inhibition by Echinacea purpurea and choice of substrate for the evaluation of herbal inhibition. Basic Clin. Pharmacol. Toxicol., 2008, 103(5), 445-449.
[http://dx.doi.org/10.1111/j.1742-7843.2008.00307.x] [PMID: 18947363]
[55]
Søholm, B. Clinical improvement of memory and other cognitive functions by Ginkgo biloba: review of relevant literature. Adv. Ther., 1998, 15(1), 54-65.
[PMID: 10178638]
[56]
Isah, T. Rethinking Ginkgo biloba L.: Medicinal uses and conservation. Pharmacogn. Rev., 2015, 9(18), 140-148.
[http://dx.doi.org/10.4103/0973-7847.162137] [PMID: 26392712]
[57]
Kressmann, S.; Müller, W.E.; Blume, H.H. Pharmaceutical quality of different Ginkgo biloba brands. J. Pharm. Pharmacol., 2002, 54(5), 661-669.
[http://dx.doi.org/10.1211/0022357021778970] [PMID: 12005361]
[58]
Liebgott, T.; Miollan, M.; Berchadsky, Y.; Drieu, K.; Culcasi, M.; Pietri, S. Complementary cardioprotective effects of flavonoid metabolites and terpenoid constituents of Ginkgo biloba extract (EGb 761) during ischemia and reperfusion. Basic Res. Cardiol., 2000, 95(5), 368-377.
[http://dx.doi.org/10.1007/s003950070035] [PMID: 11099163]
[59]
Kleijnen, J.; Knipschild, P. Ginkgo biloba. Lancet, 1992, 340(8828), 1136-1139.
[http://dx.doi.org/10.1016/0140-6736(92)93158-J] [PMID: 1359218]
[60]
Schneider, B. Ginkgo biloba extract in peripheral arterial diseases. Meta-analysis of controlled clinical studies. Arzneimittelforschung, 1992, 42(4), 428-436.
[PMID: 1386514]
[61]
Le Bars, P.L.; Katz, M.M.; Berman, N.; Itil, T.M.; Freedman, A.M.; Schatzberg, A.F. A placebo-controlled, double-blind, randomized trial of an extract of Ginkgo biloba for dementia. North American EGb Study Group. JAMA, 1997, 278(16), 1327-1332.
[http://dx.doi.org/10.1001/jama.1997.03550160047037] [PMID: 9343463]
[62]
von Moltke, L.L.; Weemhoff, J.L.; Bedir, E.; Khan, I.A.; Harmatz, J.S.; Goldman, P.; Greenblatt, D.J. Inhibition of human cytochromes P450 by components of Ginkgo biloba. J. Pharm. Pharmacol., 2004, 56(8), 1039-1044.
[http://dx.doi.org/10.1211/0022357044021] [PMID: 15285849]
[63]
Gaudineau, C.; Beckerman, R.; Welbourn, S.; Auclair, K. Inhibition of human P450 enzymes by multiple constituents of the Ginkgo biloba extract. Biochem. Biophys. Res. Commun., 2004, 318(4), 1072-1078.
[http://dx.doi.org/10.1016/j.bbrc.2004.04.139] [PMID: 15147983]
[64]
Fuchikami, H.; Satoh, H.; Tsujimoto, M.; Ohdo, S.; Ohtani, H.; Sawada, Y. Effects of herbal extracts on the function of human organic anion-transporting polypeptide OATP-B. Drug Metab. Dispos., 2006, 34(4), 577-582.
[http://dx.doi.org/10.1124/dmd.105.007872] [PMID: 16415120]
[65]
Hellum, B.H.; Nilsen, O.G. In vitro inhibition of CYP3A4 metabolism and P-glycoprotein-mediated transport by trade herbal products. Basic Clin. Pharmacol. Toxicol., 2008, 102(5), 466-475.
[http://dx.doi.org/10.1111/j.1742-7843.2008.00227.x] [PMID: 18331390]
[66]
Mandery, K.; Bujok, K.; Schmidt, I.; Keiser, M.; Siegmund, W.; Balk, B.; König, J.; Fromm, M.F.; Glaeser, H. Influence of the flavonoids apigenin, kaempferol, and quercetin on the function of organic anion transporting polypeptides 1A2 and 2B1. Biochem. Pharmacol., 2010, 80(11), 1746-1753.
[http://dx.doi.org/10.1016/j.bcp.2010.08.008] [PMID: 20797388]
[67]
Yeung, E.Y.; Sueyoshi, T.; Negishi, M.; Chang, T.K. Identification of Ginkgo biloba as a novel activator of pregnane X receptor. Drug Metab. Dispos., 2008, 36(11), 2270-2276.
[http://dx.doi.org/10.1124/dmd.108.023499] [PMID: 18725505]
[68]
Lau, A.J.; Yang, G.; Rajaraman, G.; Baucom, C.C.; Chang, T.K. Human pregnane X receptor agonism by Ginkgo biloba extract: assessment of the role of individual ginkgolides. J. Pharmacol. Exp. Ther., 2010, 335(3), 771-780.
[http://dx.doi.org/10.1124/jpet.110.172338] [PMID: 20739453]
[69]
Umegaki, K.; Taki, Y.; Endoh, K.; Taku, K.; Tanabe, H.; Shinozuka, K.; Sugiyama, T. Bilobalide in Ginkgo biloba extract is a major substance inducing hepatic CYPs. J. Pharm. Pharmacol., 2007, 59(6), 871-877.
[http://dx.doi.org/10.1211/jpp.59.6.0014] [PMID: 17637180]
[70]
Mancuso, C.; Santangelo, R. Panax ginseng and Panax quinquefolius: From pharmacology to toxicology. Food Chem. Toxicol., 2017, 107(Pt A), 362-372.
[71]
Sorensen, H.; Sonne, J. A double-masked study of the effects of ginseng on cognitive functions. Curr. Ther. Res. Clin. Exp., 1996, 57, 959-968.
[http://dx.doi.org/10.1016/S0011-393X(96)80114-7]
[72]
D’Angelo, L.; Grimaldi, R.; Caravaggi, M.; Marcoli, M.; Perucca, E.; Lecchini, S.; Frigo, G.M.; Crema, A. A double-blind, placebo-controlled clinical study on the effect of a standardized ginseng extract on psychomotor performance in healthy volunteers. J. Ethnopharmacol., 1986, 16(1), 15-22.
[http://dx.doi.org/10.1016/0378-8741(86)90063-2] [PMID: 3528672]
[73]
Ellis, J.M.; Reddy, P. Effects of Panax ginseng on quality of life. Ann. Pharmacother., 2002, 36(3), 375-379.
[http://dx.doi.org/10.1345/aph.1A245] [PMID: 11895046]
[74]
Wiklund, I.K.; Mattsson, L.A.; Lindgren, R.; Limoni, C. Effects of a standardized ginseng extract on quality of life and physiological parameters in symptomatic postmenopausal women: A double-blind, placebo-controlled trial. Int. J. Clin. Pharmacol. Res., 1999, 19(3), 89-99.
[PMID: 10761538]
[75]
Scaglione, F.; Ferrara, F.; Dugnani, S.; Falchi, M.; Santoro, G.; Fraschini, F. Immunomodulatory effects of two extracts of Panax ginseng C.A. Meyer. Drugs Exp. Clin. Res., 1990, 16(10), 537-542.
[PMID: 2100737]
[76]
Scaglione, F.; Weiser, K.; Alessandria, M. Effects of the standardized ginseng extract G115® in patients with chronic bronchitis: a nonblinded, randomised, comparative pilot study. Clin. Drug Invest. [New Zealand], 2001, 21, 41-45.
[http://dx.doi.org/10.2165/00044011-200121010-00006]
[77]
Sotaniemi, E.A.; Haapakoski, E.; Rautio, A. Ginseng therapy in non-insulin-dependent diabetic patients. Diabetes Care, 1995, 18(10), 1373-1375.
[http://dx.doi.org/10.2337/diacare.18.10.1373] [PMID: 8721940]
[78]
Yun, T.K.; Choi, S.Y. Non-organ specific cancer prevention of ginseng: a prospective study in Korea. Int. J. Epidemiol., 1998, 27(3), 359-364.
[http://dx.doi.org/10.1093/ije/27.3.359] [PMID: 9698120]
[79]
Tam, D.N.H.; Truong, D.H.; Nguyen, T.T.H.; Quynh, L.N.; Tran, L.; Nguyen, H.D.; Shamandy, B.E.; Le, T.M.H.; Tran, D.K.; Sayed, D.; Vu, V.V.; Mizukami, S.; Hirayama, K.; Huy, N.T. Ginsenoside Rh1: a systematic review of its pharmacological properties. Planta Med., 2018, 84(3), 139-152.
[http://dx.doi.org/10.1055/s-0043-124087] [PMID: 29329463]
[80]
Wu, L.X.; Guo, C.X.; Qu, Q.; Yu, J.; Chen, W.Q.; Wang, G.; Fan, L.; Li, Q.; Zhang, W.; Zhou, H.H. Effects of natural products on the function of human organic anion transporting polypeptide 1B1. Xenobiotica, 2012, 42(4), 339-348.
[http://dx.doi.org/10.3109/00498254.2011.623796] [PMID: 22117525]
[81]
Henderson, G.L.; Harkey, M.R.; Gershwin, M.E.; Hackman, R.M.; Stern, J.S.; Stresser, D.M. Effects of ginseng components on c-DNA-expressed cytochrome P450 enzyme catalytic activity. Life Sci., 1999, 65(15), PL209-PL214.
[http://dx.doi.org/10.1016/S0024-3205(99)00407-5] [PMID: 10574228]
[82]
He, N.; Xie, H.G.; Collins, X.; Edeki, T.; Yan, Z. Effects of individual ginsenosides, ginkgolides and flavonoids on CYP2C19 and CYP2D6 activity in human liver microsomes. Clin. Exp. Pharmacol. Physiol., 2006, 33(9), 813-815.
[http://dx.doi.org/10.1111/j.1440-1681.2006.04445.x] [PMID: 16922812]
[83]
Fang, Z.Z.; Cao, Y.F.; Hu, C.M.; Hong, M.; Sun, X.Y.; Ge, G.B.; Liu, Y.; Zhang, Y.Y.; Yang, L.; Sun, H.Z. Structure-inhibition relationship of ginsenosides towards UDP-glucuronosyltransferases (UGTs). Toxicol. Appl. Pharmacol., 2013, 267(2), 149-154.
[http://dx.doi.org/10.1016/j.taap.2012.12.019] [PMID: 23306165]
[84]
Li, Y.; Wang, Q.; Yao, X.; Li, Y. Induction of CYP3A4 and MDR1 gene expression by baicalin, baicalein, chlorogenic acid, and ginsenoside Rf through constitutive androstane receptor- and pregnane X receptor-mediated pathways. Eur. J. Pharmacol., 2010, 640(1-3), 46-54.
[http://dx.doi.org/10.1016/j.ejphar.2010.05.017] [PMID: 20580705]
[85]
Wang, Y.; Ye, X.; Ma, Z.; Liang, Q.; Lu, B.; Tan, H.; Xiao, C.; Zhang, B.; Gao, Y. Induction of cytochrome P450 1A1 expression by ginsenoside Rg1 and Rb1 in HepG2 cells. Eur. J. Pharmacol., 2008, 601(1-3), 73-78.
[http://dx.doi.org/10.1016/j.ejphar.2008.10.057] [PMID: 19022240]
[86]
Lee, S.H.; Ahn, Y.M.; Ahn, S.Y.; Doo, H.K.; Lee, B.C. Interaction between warfarin and Panax ginseng in ischemic stroke patients. J. Altern. Complement. Med., 2008, 14(6), 715-721.
[http://dx.doi.org/10.1089/acm.2007.0799] [PMID: 18637764]
[87]
Bilgi, N.; Bell, K.; Ananthakrishnan, A.N.; Atallah, E. Imatinib and Panax ginseng: a potential interaction resulting in liver toxicity. Ann. Pharmacother., 2010, 44(5), 926-928.
[http://dx.doi.org/10.1345/aph.1M715] [PMID: 20332334]
[88]
Kim, M.G.; Kim, Y.; Jeon, J.Y.; Kim, D.S. Effect of fermented red ginseng on cytochrome P450 and P-glycoprotein activity in healthy subjects, as evaluated using the cocktail approach. Br. J. Clin. Pharmacol., 2016, 82(6), 1580-1590.
[http://dx.doi.org/10.1111/bcp.13080] [PMID: 27495955]
[89]
Nikaido, T.; Ohmoto, T.; Sankawa, U.; Tanaka, O.; Kasai, R.; Shoji, J.; Sanada, S.; Hiai, S.; Yokoyama, H.; Oura, H.; Kawashima, Y. Inhibitors of cyclic AMP phosphodiesterase in Panax ginseng C. A. Meyer and Panax japonicus C. A. Meyer. Chem. Pharm. Bull. (Tokyo), 1984, 32(4), 1477-1483.
[http://dx.doi.org/10.1248/cpb.32.1477] [PMID: 6088096]
[90]
Norelli, L.J.; Xu, C. Manic psychosis associated with ginseng: a report of two cases and discussion of the literature. J. Diet. Suppl., 2015, 12(2), 119-125.
[http://dx.doi.org/10.3109/19390211.2014.902001] [PMID: 24689505]
[91]
2021. US FDA. Sales of Supplements Containing Ephedrine Alkaloids (Ephedra) Prohibited. Available from: http://web.archive.org/web/20080126150250/www.fda.gov/oc/initiatives/ephedra/february200 4/Accessed April 22, 2021
[92]
Fong, T.L.; Klontz, K.C.; Canas-Coto, A.; Casper, S.J.; Durazo, F.A.; Davern, T.J., II; Hayashi, P.; Lee, W.M.; Seeff, L.B. Hepatotoxicity due to hydroxycut: a case series. Am. J. Gastroenterol., 2010, 105(7), 1561-1566.
[http://dx.doi.org/10.1038/ajg.2010.5] [PMID: 20104221]
[93]
Dara, L.; Hewett, J.; Lim, J.K. Hydroxycut hepatotoxicity: a case series and review of liver toxicity from herbal weight loss supplements. World J. Gastroenterol., 2008, 14(45), 6999-7004.
[http://dx.doi.org/10.3748/wjg.14.6999] [PMID: 19058338]
[94]
Zaidan, J.; Tabet, R.; Karam, B.; Daneshvar, F.; Raza, M.; Bekheit, S. Asystole caused by Hydroxycut Hardcore: A case report and literature review. Ann. Noninvasive Electrocardiol., 2018, 23(3), e12479.
[http://dx.doi.org/10.1111/anec.12479] [PMID: 28653348]
[95]
Adike, A.; Smith, M.L.; Chervenak, A.; Vargas, H.E. Hydroxycut-related vanishing bile duct syndrome. Clin. Gastroenterol. Hepatol., 2017, 15(1), 142-144.
[http://dx.doi.org/10.1016/j.cgh.2016.04.028] [PMID: 27151488]
[96]
Lindstrom, L. History, folklore, traditional and current uses of kava. Kava from Ethnology to Pharmacology; Singh, Y.N., Ed.; CRC Press: Boca Raton, 2004, pp. 10-28.
[http://dx.doi.org/10.1201/9781420023374-4]
[97]
Singh, Y.N.; Singh, N.N. Therapeutic potential of kava in the treatment of anxiety disorders. CNS Drugs, 2002, 16(11), 731-743.
[http://dx.doi.org/10.2165/00023210-200216110-00002] [PMID: 12383029]
[98]
Sarris, J.; Byrne, G.J.; Bousman, C.A.; Cribb, L.; Savage, K.M.; Holmes, O.; Murphy, J.; Macdonald, P.; Short, A.; Nazareth, S.; Jennings, E.; Thomas, S.R.; Ogden, E.; Chamoli, S.; Scholey, A.; Stough, C. Kava for generalised anxiety disorder: A 16-week double-blind, randomised, placebo-controlled study. Aust. N. Z. J. Psychiatry, 2020, 54(3), 288-297.
[http://dx.doi.org/10.1177/0004867419891246] [PMID: 31813230]
[99]
Kuchta, K.; de Nicola, P.; Schmidt, M. Randomized, dose‐controlled double‐blind trial: Efficacy of an ethanolic kava (Piper methysticum rhizome) extract for the treatment of anxiety in elderly patients. Tradit. Kampo Med., 2018, 5(1), 3-10.
[http://dx.doi.org/10.1002/tkm2.1079]
[100]
Cagnacci, A.; Arangino, S.; Renzi, A.; Zanni, A.L.; Malmusi, S.; Volpe, A. Kava-Kava administration reduces anxiety in perimenopausal women. Maturitas, 2003, 44(2), 103-109.
[http://dx.doi.org/10.1016/S0378-5122(02)00317-1] [PMID: 12590005]
[101]
Volz, H.P.; Kieser, M. Kava-kava extract WS 1490 versus placebo in anxiety disorders--a randomized placebo-controlled 25-week outpatient trial. Pharmacopsychiatry, 1997, 30(1), 1-5.
[http://dx.doi.org/10.1055/s-2007-979474] [PMID: 9065962]
[102]
Smith, K.; Leiras, C. The effectiveness and safety of Kava Kava for treating anxiety symptoms: A systematic review and analysis of randomized clinical trials. Complement. Ther. Clin. Pract., 2018, 33, 107-117.
[http://dx.doi.org/10.1016/j.ctcp.2018.09.003] [PMID: 30396607]
[103]
McGhee, H.W. From the Centers for Disease Control and Prevention. Hepatic toxicity possibly associated with kava-containing products--United States, Germany, and Switzerland, 1999-2002. JAMA, 2003, 289(1), 36-37.
[http://dx.doi.org/10.1001/jama.289.1.36] [PMID: 12515265]
[104]
Kuchta, K.; Schmidt, M.; Nahrstedt, A. German kava ban lifted by court: The alleged hepatotoxicity of kava (Piper methysticum) as a case of ill-defined herbal drug identity, lacking quality control, and misguided regulatory politics. Planta Med., 2015, 81(18), 1647-1653.
[http://dx.doi.org/10.1055/s-0035-1558295] [PMID: 26695707]
[105]
Mathews, J.M.; Etheridge, A.S.; Black, S.R. Inhibition of human cytochrome P450 activities by kava extract and kavalactones. Drug Metab. Dispos., 2002, 30(11), 1153-1157.
[http://dx.doi.org/10.1124/dmd.30.11.1153] [PMID: 12386118]
[106]
Unger, M.; Holzgrabe, U.; Jacobsen, W.; Cummins, C.; Benet, L.Z. Inhibition of cytochrome P450 3A4 by extracts and kavalactones of Piper methysticum (Kava-Kava). Planta Med., 2002, 68(12), 1055-1058.
[http://dx.doi.org/10.1055/s-2002-36360] [PMID: 12494328]
[107]
Klohs, M.W.; Keller, F.; Williams, R.E.; Toekes, M.I.; Cronheim, G.E. A chemical and pharmacological investigation of Piper methysticum Forst. J. Med. Pharm. Chem., 1959, 1(1), 95-103.
[http://dx.doi.org/10.1021/jm50002a007] [PMID: 13655031]
[108]
Meyer, H.J. Pharmakologie der wirksamen prinzipien des Kawa-rhizoms (Piper methysticum Forst.). Arch. Int. Pharmacodyn. Ther., 1962, 138, 505-536.
[PMID: 13935274]
[109]
Herberg, K.W. Alltagssicherheit unter kava-kava extrakt, bromazepam und deren kombination. Z. Allgemeinmed., 1996, 72, 973-977.
[110]
Baum, S.S.; Hill, R.; Rommelspacher, H. Effect of kava extract and individual kavapyrones on neurotransmitter levels in the nucleus accumbens of rats. Prog. Neuropsychopharmacol. Biol. Psychiatry, 1998, 22(7), 1105-1120.
[http://dx.doi.org/10.1016/S0278-5846(98)00062-1] [PMID: 9829291]
[111]
Eggleston, W.; Stoppacher, R.; Suen, K.; Marraffa, J.M.; Nelson, L.S. Kratom use and toxicities in the united states. Pharmacotherapy, 2019, 39(7), 775-777.
[http://dx.doi.org/10.1002/phar.2280] [PMID: 31099038]
[112]
Kruegel, A.C.; Gassaway, M.M.; Kapoor, A.; Váradi, A.; Majumdar, S.; Filizola, M.; Javitch, J.A.; Sames, D. Synthetic and receptor signaling explorations of the mitragyna alkaloids: Mitragynine as an atypical molecular framework for opioid receptor modulators. J. Am. Chem. Soc., 2016, 138(21), 6754-6764.
[http://dx.doi.org/10.1021/jacs.6b00360] [PMID: 27192616]
[113]
Johnson, L.E.; Balyan, L.; Magdalany, A.; Saeed, F.; Salinas, R.; Wallace, S.; Veltri, C.A.; Swogger, M.T.; Walsh, Z.; Grundmann, O. The potential for kratom as an antidepressant and antipsychotic. Yale J. Biol. Med., 2020, 93(2), 283-289.
[PMID: 32607089]
[114]
Manda, V.K.; Avula, B.; Dale, O.R.; Ali, Z.; Khan, I.A.; Walker, L.A.; Khan, S.I. PXR mediated induction of CYP3A4, CYP1A2, and P-gp by Mitragyna speciosa and its alkaloids. Phytother. Res., 2017, 31(12), 1935-1945.
[http://dx.doi.org/10.1002/ptr.5942] [PMID: 29071751]
[115]
Tanna, R.S.; Tian, D.D.; Cech, N.B.; Oberlies, N.H.; Rettie, A.E.; Thummel, K.E.; Paine, M.F. Refined prediction of pharmacokinetic kratom-drug interactions: time-dependent inhibition considerations. J. Pharmacol. Exp. Ther., 2021, 376(1), 64-73.
[http://dx.doi.org/10.1124/jpet.120.000270] [PMID: 33093187]
[116]
Kong, W.M.; Chik, Z.; Ramachandra, M.; Subramaniam, U.; Aziddin, R.E.; Mohamed, Z. Evaluation of the effects of Mitragyna speciosa alkaloid extract on cytochrome P450 enzymes using a high throughput assay. Molecules, 2011, 16(9), 7344-7356.
[http://dx.doi.org/10.3390/molecules16097344] [PMID: 21876481]
[117]
Kamble, S.H.; Sharma, A.; King, T.I.; León, F.; McCurdy, C.R.; Avery, B.A. Metabolite profiling and identification of enzymes responsible for the metabolism of mitragynine, the major alkaloid of Mitragyna speciosa (kratom). Xenobiotica, 2019, 49(11), 1279-1288.
[http://dx.doi.org/10.1080/00498254.2018.1552819] [PMID: 30547698]
[118]
Whistler, W.A. Traditional and herbal medicine in the Cook Islands. J. Ethnopharmacol., 1985, 13(3), 239-280.
[http://dx.doi.org/10.1016/0378-8741(85)90072-8] [PMID: 3903354]
[119]
Wang, M.Y.; West, B.J.; Jensen, C.J.; Nowicki, D.; Su, C.; Palu, A.K.; Anderson, G. Morinda citrifolia (Noni): a literature review and recent advances in Noni research. Acta Pharmacol. Sin., 2002, 23(12), 1127-1141.
[PMID: 12466051]
[120]
Eck, P.O.; Shah, P.A.; Nerurkar, P.V. Modulation of cytochrome P450 1A2 and 3A4 by Morinda citrifolia (noni), Euterpe oleracea (acai), Lycium barbarum (goji) and Garcinia mangostana (mangosteen). FASEB J., 2009, 23, 688-6.
[http://dx.doi.org/10.1096/fasebj.23.1_supplement.688.6]
[121]
Santiago, K.; Gaikwad, A.; Coffer, I.I.L.; Smith, J.A. Evaluation of the hepatic metabolism and antitumor activity of noni juice (Morinda citrifolia L.) in combination with chemotherapy. J. Soc. Integr. Oncol., 2010, 8, 89-94.
[122]
Chandra, R.H.; Veeresham, C. Herb-drug interaction of noni juice and Ginkgo biloba with phenytoin. Pharmacogn. J., 2011, 2(18), 33-41.
[http://dx.doi.org/10.1016/S0975-3575(11)80023-4]
[123]
Liu, C.; Wu, Y.F. Efficacy of 308nm excimer laser plus piperine in the treatment of vitiligo. J. Dermatol. Venereol., 2016, 38(4), 235-238.
[124]
Ma, Z.G.; Yuan, Y.P.; Zhang, X.; Xu, S.C.; Wang, S.S.; Tang, Q.Z. Piperine attenuates pathological cardiac fibrosis via PPAR-γ/AKT pathways. EBioMedicine, 2017, 18, 179-187.
[http://dx.doi.org/10.1016/j.ebiom.2017.03.021] [PMID: 28330809]
[125]
Bhardwaj, R.K.; Glaeser, H.; Becquemont, L.; Klotz, U.; Gupta, S.K.; Fromm, M.F. Piperine, a major constituent of black pepper, inhibits human P-glycoprotein and CYP3A4. J. Pharmacol. Exp. Ther., 2002, 302(2), 645-650.
[http://dx.doi.org/10.1124/jpet.102.034728] [PMID: 12130727]
[126]
Amsterdam, J.D.; Panossian, A.G. Rhodiola rosea L. as a putative botanical antidepressant. Phytomedicine, 2016, 23(7), 770-783.
[http://dx.doi.org/10.1016/j.phymed.2016.02.009] [PMID: 27013349]
[127]
Cropley, M.; Banks, A.P.; Boyle, J. The effects of Rhodiola rosea L. extract on anxiety, stress, cognition and other mood symptoms: Rhodiola rosea, mood and cognition. Phytother. Res., 2015, 29(12), 1934-1939.
[http://dx.doi.org/10.1002/ptr.5486] [PMID: 26502953]
[128]
Mannucci, C.; Navarra, M.; Calzavara, E.; Caputi, A.P.; Calapai, G. Serotonin involvement in Rhodiola rosea attenuation of nicotine withdrawal signs in rats. Phytomedicine, 2012, 19(12), 1117-1124.
[http://dx.doi.org/10.1016/j.phymed.2012.07.001] [PMID: 22921986]
[129]
Qin, Y.J.; Zeng, Y.S.; Zhou, C.C.; Li, Y.; Zhong, Z.Q. Effects of Rhodiola rosea on level of 5-hydroxytryptamine, cell proliferation and differentiation, and number of neuron in cerebral hippocampus of rats with depression induced by chronic mild stress. Zhongguo Zhongyao Zazhi, 2008, 33(23), 2842-2846.
[PMID: 19260327]
[130]
Stancheva, S.L.; Mosharrof, A. Effect of the extract of Rhodiola rosea L. on the content of the brain biogenic monoamines. Med. Physiol. Dokl. Bulg. Akad. Nauk., 1987, 40, 85-87.
[131]
Chen, Q.G.; Zeng, Y.S.; Qu, Z.Q.; Tang, J.Y.; Qin, Y.J.; Chung, P.; Wong, R.; Hägg, U. The effects of Rhodiola rosea extract on 5-HT level, cell proliferation and quantity of neurons at cerebral hippocampus of depressive rats. Phytomedicine, 2009, 16(9), 830-838.
[http://dx.doi.org/10.1016/j.phymed.2009.03.011] [PMID: 19403286]
[132]
Bystritsky, A.; Kerwin, L.; Feusner, J.D. A pilot study of Rhodiola rosea (Rhodax) for generalized anxiety disorder (GAD). J. Altern. Complement. Med., 2008, 14(2), 175-180.
[http://dx.doi.org/10.1089/acm.2007.7117] [PMID: 18307390]
[133]
Darbinyan, V.; Aslanyan, G.; Amroyan, E.; Gabrielyan, E.; Malmström, C.; Panossian, A. Clinical trial of Rhodiola rosea L. extract SHR-5 in the treatment of mild to moderate depression. Nord. J. Psychiatry, 2007, 61(5), 343-348.
[http://dx.doi.org/10.1080/08039480701643290] [PMID: 17990195]
[134]
Concerto, C.; Infortuna, C.; Muscatello, M.R.A.; Bruno, A.; Zoccali, R.; Chusid, E.; Aguglia, E.; Battaglia, F. Exploring the effect of adaptogenic Rhodiola rosea extract on neuroplasticity in humans. Complement. Ther. Med., 2018, 41, 141-146.
[http://dx.doi.org/10.1016/j.ctim.2018.09.013] [PMID: 30477830]
[135]
Darbinyan, V.; Kteyan, A.; Panossian, A.; Gabrielian, E.; Wikman, G.; Wagner, H. Rhodiola rosea in stress induced fatigue--a double blind cross-over study of a standardized extract SHR-5 with a repeated low-dose regimen on the mental performance of healthy physicians during night duty. Phytomedicine, 2000, 7(5), 365-371.
[http://dx.doi.org/10.1016/S0944-7113(00)80055-0] [PMID: 11081987]
[136]
De Bock, K.; Eijnde, B.O.; Ramaekers, M.; Hespel, P. Acute Rhodiola rosea intake can improve endurance exercise performance. Int. J. Sport Nutr. Exerc. Metab., 2004, 14(3), 298-307.
[http://dx.doi.org/10.1123/ijsnem.14.3.298] [PMID: 15256690]
[137]
Xu, W.; Zhang, T.; Wang, Z.; Liu, T.; Liu, Y.; Cao, Z.; Sui, Z. Two potent cytochrome P450 2D6 inhibitors found in Rhodiola rosea. Pharmazie, 2013, 68(12), 974-976.
[PMID: 24400445]
[138]
Thu, O.K.; Nilsen, O.G.; Hellum, B. In vitro inhibition of cytochrome P-450 activities and quantification of constituents in a selection of commercial Rhodiola rosea products. Pharm. Biol., 2016, 54(12), 3249-3256.
[http://dx.doi.org/10.1080/13880209.2016.1223145] [PMID: 27572116]
[139]
Thu, O.K.; Spigset, O.; Nilsen, O.G.; Hellum, B. Effect of commercial Rhodiola rosea on CYP enzyme activity in humans. Eur. J. Clin. Pharmacol., 2016, 72(3), 295-300.
[http://dx.doi.org/10.1007/s00228-015-1988-7] [PMID: 26613955]
[140]
Bilia, A.R.; Gallori, S.; Vincieri, F.F.St.St. John’s wort and depression: efficacy, safety and tolerability-an update. Life Sci., 2002, 70(26), 3077-3096.
[http://dx.doi.org/10.1016/S0024-3205(02)01566-7] [PMID: 12008092]
[141]
Williams, J.W., Jr; Mulrow, C.D.; Chiquette, E.; Noël, P.H.; Aguilar, C.; Cornell, J. A systematic review of newer pharmacotherapies for depression in adults: evidence report summary. Ann. Intern. Med., 2000, 132(9), 743-756.
[http://dx.doi.org/10.7326/0003-4819-132-9-200005020-00011] [PMID: 10787370]
[142]
Müller, T.; Mannel, M.; Murck, H.; Rahlfs, V.W. Treatment of somatoform disorders with St. John’s wort: a randomized, double-blind and placebo-controlled trial. Psychosom. Med., 2004, 66(4), 538-547.
[http://dx.doi.org/10.1097/01.psy.0000128900.13711.5b] [PMID: 15272100]
[143]
Stevinson, C.; Ernst, E. A pilot study of Hypericum perforatum for the treatment of premenstrual syndrome. BJOG, 2000, 107(7), 870-876.
[http://dx.doi.org/10.1111/j.1471-0528.2000.tb11085.x] [PMID: 10901558]
[144]
Winkel, R.; Koritsch, H.D.; Piayda, H. St John’s wort extract LI 160 in depressive, alcohol-addicted patients. Phytomedicine, 2000, 7(Suppl. 2), 19.
[145]
Singer, A.; Wonnemann, M.; Müller, W.E. Hyperforin, a major antidepressant constituent of St. John’s Wort, inhibits serotonin uptake by elevating free intracellular Na+1. J. Pharmacol. Exp. Ther., 1999, 290(3), 1363-1368.
[PMID: 10454515]
[146]
Ruschitzka, F.; Meier, P.J.; Turina, M.; Lüscher, T.F.; Noll, G. Acute heart transplant rejection due to Saint John’s wort. Lancet, 2000, 355(9203), 548-549.
[http://dx.doi.org/10.1016/S0140-6736(99)05467-7] [PMID: 10683008]
[147]
Piscitelli, S.C.; Burstein, A.H.; Chaitt, D.; Alfaro, R.M.; Falloon, J. Indinavir concentrations and St John’s wort. Lancet, 2000, 355(9203), 547-548.
[http://dx.doi.org/10.1016/S0140-6736(99)05712-8] [PMID: 10683007]
[148]
Schwarz, U.I.; Büschel, B.; Kirch, W. Unwanted pregnancy on self-medication with St John’s wort despite hormonal contraception. Br. J. Clin. Pharmacol., 2003, 55(1), 112-113.
[http://dx.doi.org/10.1046/j.1365-2125.2003.01716.x] [PMID: 12534648]
[149]
Bag, A.; Bhattacharyya, S.K.; Chattopadhyay, R.R. The development of Terminalia chebula Retz. (Combretaceae) in clinical research. Asian Pac. J. Trop. Biomed., 2013, 3(3), 244-252.
[http://dx.doi.org/10.1016/S2221-1691(13)60059-3] [PMID: 23620847]
[150]
Lakshmi, K.; Karishma, S.K.; Sekhar, N.C.; Babu, N.A.; Kumar, B.N. Terminalia chebula Retz improve memory and learning in Alzheimer’s Model:(Experimental Study in Rat). Res. J. Pharm. Technol., 2018, 11(11), 4888-4891.
[151]
Jokar, A.; Masoomi, F.; Sadeghpour, O.; Nassiri-Toosi, M.; Hamedi, S. Potential therapeutic applications for Terminalia chebula in Iranian traditional medicine. J. Tradit. Chin. Med., 2016, 36(2), 250-254.
[http://dx.doi.org/10.1016/S0254-6272(16)30035-8] [PMID: 27400482]
[152]
Kumar, S.; Shankar, V. Medicinal plants of the Indian desert: Commiphora wightii (Arnott). Bhand. J. Arid Environ., 1982, 5(1), 1-1.
[http://dx.doi.org/10.1016/S0140-1963(18)31458-7]
[153]
Shen, T.; Li, G.H.; Wang, X.N.; Lou, H.X. The genus Commiphora: a review of its traditional uses, phytochemistry and pharmacology. J. Ethnopharmacol., 2012, 142(2), 319-330.
[http://dx.doi.org/10.1016/j.jep.2012.05.025] [PMID: 22626923]
[154]
Claudel, T.; Staels, B.; Kuipers, F. The Farnesoid X receptor: a molecular link between bile acid and lipid and glucose metabolism. Arterioscler. Thromb. Vasc. Biol., 2005, 25(10), 2020-2030.
[http://dx.doi.org/10.1161/01.ATV.0000178994.21828.a7] [PMID: 16037564]
[155]
Chhonker, Y.S.; Chandasana, H.; Bala, V.; Mukkavilli, R.; Kumar, D.; Vangala, S.; Bhatta, R.S. In-vitro metabolism, CYP profiling and metabolite identification of E- and Z- guggulsterone, a potent hypolipidmic agent. J. Pharm. Biomed. Anal., 2018, 160, 202-211.
[http://dx.doi.org/10.1016/j.jpba.2018.06.047] [PMID: 30099292]
[156]
Ponnusankar, S.; Pandit, S.; Venkatesh, M.; Bandyopadhyay, A.; Mukherjee, P.K. Cytochrome P450 inhibition assay for standardized extract of Terminalia chebula Retz. Phytother. Res., 2011, 25(1), 151-154.
[http://dx.doi.org/10.1002/ptr.2993] [PMID: 20623819]
[157]
Dietz, B.M.; Mahady, G.B.; Pauli, G.F.; Farnsworth, N.R. Valerian extract and valerenic acid are partial agonists of the 5-HT5a receptor in vitro. Brain Res. Mol. Brain Res., 2005, 138(2), 191-197.
[http://dx.doi.org/10.1016/j.molbrainres.2005.04.009] [PMID: 15921820]
[158]
Lefebvre, T.; Foster, B.C.; Drouin, C.E.; Krantis, A.; Livesey, J.F.; Jordan, S.A. In vitro activity of commercial Valerian root extracts against human cytochrome P450 3A4. J. Pharm. Pharm. Sci., 2004, 7(2), 265-273.
[PMID: 15367385]
[159]
Bogacz, A.; Mrozikiewicz, P.M.; Karasiewicz, M.; Bartkowiak-Wieczorek, J.; Majchrzycki, M.; Mikolajczak, P.L.; Ozarowski, M.; Grzeskowiak, E. The influence of standardized Valeriana officinalis extract on the CYP3A1 gene expression by nuclear receptors in in vivo model. BioMed Res. Int., 2014, 2014, 819093.
[http://dx.doi.org/10.1155/2014/819093] [PMID: 25302309]
[160]
Fasinu, P.S.; Bouic, P.J.; Rosenkranz, B. An overview of the evidence and mechanisms of herb-drug interactions. Front. Pharmacol., 2012, 3, 69.
[http://dx.doi.org/10.3389/fphar.2012.00069] [PMID: 22557968]
[161]
Li, J.; Gödecke, T.; Chen, S.N.; Imai, A.; Lankin, D.C.; Farnsworth, N.R.; Pauli, G.F.; van Breemen, R.B.; Nikolić, D. In vitro metabolic interactions between black cohosh (Cimicifuga racemosa) and tamoxifen via inhibition of cytochromes P450 2D6 and 3A4. Xenobiotica, 2011, 41(12), 1021-1030.
[http://dx.doi.org/10.3109/00498254.2011.603385] [PMID: 21827327]
[162]
Ganzera, M.; Schneider, P.; Stuppner, H. Inhibitory effects of the essential oil of chamomile (Matricaria recutita L.) and its major constituents on human cytochrome P450 enzymes. Life Sci., 2006, 78(8), 856-861.
[http://dx.doi.org/10.1016/j.lfs.2005.05.095] [PMID: 16137701]

Rights & Permissions Print Cite
Article Metrics
30
1
© 2024 Bentham Science Publishers | Privacy Policy